We believe strong partnerships drive progress towards new medicines for patients
At Ribo Life Science, we combine world-class oligonucleotide discovery capabilities with proven technology to advance siRNA projects within our pipeline globally
We actively seek strategic collaborations within the siRNA field. Also, partnerships to accelerate the advancement of our high-potential assets and co-create value with partners
Collaborate on diseases we can target via the liver, metabolic disorders, cardiovascular, and obesity
Work together with others on kidney diseases, also targeting the CNS and potentially other tissues and cells
Share our proven expertise in innovative drug development, with strong clinical and regulatory capabilities
Work with partners with strong commercial capabilities and global market insight
2024
Ribo signed up with Boehringer Ingelheim to develop new treatments for people with liver diseases.
2023
Ribo granted Qilu Pharmaceutical Co., Ltd. the rights to develop, manufacture and commercialize RBD7022 in Greater China region.
